Second Solid Cancers after Allogeneic Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Nov 01, 2014
- Source ID
- 10.1016/j.bbmt.2014.07.009
Entities
People
- Alison W. Loren
- Amir Steinberg
- Bipin N Savani
- Christine Duncan
- David A. Jacobsohn
- David Buchbinder
- David I. Marks
- Gerard Socie
- Gregory A. Hale
- Harry C. Schouten
- Hillard M Lazarus
- Ibrahim Ahmed
- Jack W. Hsu
- Jean-yves Cahn
- Joerg Halter
- John R Wingard
- Jonas Mattsson
- Kasiani C. Myers
- Kimberly A. Kasow
- Linda J. Burns
- Mohamed L Sorror
- Muthalagu Ramanathan
- Nandita Khera
- Navneet S Majhail
- Naynesh R. Kamani
- Olle Ringden
- Rammurti T. Kamble
- Robert J. Hayashi
- Ruta Brazauskas
- Uday Popat
- Wael Saber
- Yoshiko Atsuta
- Zhiwei Wang
Organizations
- ARIAD Pharmaceuticals
- Amgen
- Bailey Family Foundation
- Blue Cross Blue Shield Association
- Celgene
- CellGenix (Germany)
- Children’s Leukemia Research Association
- Elevance Health, Inc.
- GSK
- Kiadis Pharma (Netherlands)
- Leukemia & Lymphoma Society
- Medical College of Wisconsin
- National Cancer Institute
- National Heart, Lung, and Blood Institute
- National Institute of Allergy and Infectious Diseases
- National Marrow Donor Program
- Office of Naval Research
- Osiris Therapeutics
- Otsuka (United States)
- Roche (United States)
- StemCyte
- Swedish Orphan Biovitrum
- Takeda Oncology
- Tarix Orphan (United States)
- Terumo BCT (United States)
- Texas Instruments